Announcement on Progress in Disposal of Repurchased Shares
Filed with SSE · · 4 pages · Chinese
Beijing Hotgen Biotech Co. Ltd. on 6ix
Earlier from Beijing Hotgen Biotech
- Announcement on Initial Sale of Repurchased Shares Through Call Auction
- Announcement on Voluntary Disclosure of Completion of the First Patient Enrollment and Dosing in the Phase II Clinical Trial of SGC001 Innovative Drug by a Subsidiary
- Announcement on Voluntary Disclosure of the Completion of First Patient Enrollment and Dosing in the Phase Ib Clinical Trial of Innovative Drug AA001 Monoclonal Antibody for Alzheimer’s Disease by an Joint-stock Company
- Announcement on Preliminary Earnings Estimate for 2025
- Earnings Preannouncement for 2025
Later from Beijing Hotgen Biotech
- Announcement on Voluntary Disclosure of Obtaining the "Acceptance Notice" for Clinical Trial Application for Subsidiary’s Innovative Drug SGT003 Injection
- Announcement on Canceling Some Restricted Stocks Granted and Not Yet Vested
- Announcement on Progress and Implementation Result of Shares Repurchase and Share Changes
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
- Announcement on Capital Increase of Joint Stock Company and Related Party Transactions
Follow Beijing Hotgen Biotech into a list and get an email when it puts out news.
Follow Beijing Hotgen Biotech